Contact

C.Y.L. Pharmazeutika GmbH
Hauptstraße 140
A-8301 Laßnitzhöhe
T: 03133 / 3222-2
F: 03133 / 3222-9
E: office@cyl-pharma.com

Oncology

Since the company was founded, the main focus was placed on the research and development of a solution for infusion (KARAL®), based on the disturbed metabolism of a tumor cell and the ultra-specific tumor cell destruction.

Welcome

C.Y.L. Pharmaceuticals (CYL) is a pharmaceutical research and development management company.

CYL sees itself as a management company, which absorbs product ideas and helps them reach market maturity by utilizing a research and development network

In this manner, CYL has taken on the task of putting pharmaceutical products for people on the market.

Company history

The idea of using products based on alpha-ketoglutaric acid and 5-HMF was developed by Dr. Groke in the mid-80s during his time as the head of drug discovery in pharmaceutics.

By 1995, Dr. Groke secured patents and all necessary related documents at the time.

Since 1998, Dr. Groke has been devoted to the utilization of alpha-ketoglutaric acid and further developments in the field.

Active ingredients

CYL is mainly concerned with the effects of special active ingredients that are already known in medicine, but have not yet been explored and used as a combination in this form. The following are the active ingredients:

  • Alpha-ketoglutaric acid (AKG)
  • 5-hydroxymethyl-furfural (5-HMF)
  • N-acetyl-seleno-L-methionine (NASeLM)
  • N-acetyl-L-methionine (NALM)

Currently, over 23,000 scientific papers (Reviews & Articles), of them over 5,000 contributions about oxidative stress parameters, have been published.

This number is still soaring and illustrates the importance of this topic in our society. In everyday life, the term oxidative stress is commonly used in connection with high stress levels, burnout, depression, and fatigue.


logo edelweiss